CD4 depletion (as shown in Supplementary Fig. 8e) did not affect tumor growth and survival induced by Flt3L+NDV treatment (Fig. 7h); however, it should be noted that CD4-specific antibodies also deplete tumor-promoting regulatory T cells, potentially masking the effects mediated by CD4+ effector T cells. This evidence concerns the gene FLT3LG and neoplasm.